Qualigen Therapeutics 1-For-50 Reverse Stock Split, Expected To Begin Trading On Split-Adjusted Basis On November 5, 2024
Qualigen Therapeutics 1-For-50 Reverse Stock Split, Expected To Begin Trading On Split-Adjusted Basis On November 5, 2024
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on November 5, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, November 5, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol "QLGN." The new CUSIP number for the common stock will be 74754R 301.
Qualigen Therapeutics, Inc.（納斯達克：QLGN）（"公司"）今天宣佈將對其普通股發行股份進行1比50的股票合併（"反向股票分割"），自2024年11月5日東部時間凌晨12:01生效。預計公司的普通股將從2024年11月5日星期二市場開盤時開始以調整後的價格交易，並將繼續在納斯達克資本市場以"QLGN"標的進行交易。普通股的新CUSIP編號將爲74754R 301。
The Reverse Stock Split is intended to increase the bid price of the common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company's stockholders authorized the reverse stock split at the Company's annual meeting of stockholders held on October 25, 2024, with the final ratio subsequently determined by the Company's Board of Directors.
反向股票分割旨在提高普通股的買盤價格，使公司能夠恢復繼續在納斯達克資本市場上市的最低買盤價格要求的合規性。公司的股東授權在2024年10月25日舉行的股東年會上進行股票合併，最終比率由公司的董事會隨後確定。
譯文內容由第三人軟體翻譯。
